cromoglicic acid   

GtoPdb Ligand ID: 7608

Synonyms: cromoglycate | cromolyn | cromolyn sodium | FPL-670 | Intal® | Opticrom® | sodium cromoglicate
cromoglicic acid is an approved drug (FDA (1984))
Compound class: Synthetic organic
Comment: Cromoglicic acid (cromolyn) is regarded as a mast cell stabilising drug, although its exact mechanism of action appears to be much more complicated.
Recent reports suggest that cromolyn inhibits glycogen synthase kinase 3β and may therefore have potential to treat diabetes and obesity [2] and may prove effective in treating insulin-induced lipoatrophy [3]. It also has reported potential anti-fibrotic action through agonism of GPR35 [1,4].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: cromoglicic acid

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 173.71
Molecular weight 468.07
XLogP 3.48
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O
Isomeric SMILES OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O
InChI InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)
InChI Key IMZMKUWMOSJXDT-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
Cromoglicic acid is available in different formulations; nasal spray is used to treat allergic rhinitis, nebulizer solution to treat asthma, eye drops to treat allergic conjunctivitis and an oral form to treat mastocytosis, dermatographic urticaria and ulcerative colitis. Clinical use in asthma has largely been replaced by the more convenient leukotriene receptor antagonists.
Mechanism Of Action and Pharmacodynamic Effects
Cromoglicic acid is considered to predominantly stabilise mast cells and inhibit their degranulation. This action supresses the release of histamine and tryptase, thus reducing the synthesis of pro-inflammatory prostaglandins and leukotrienes. The drug also inhibits the activity of other types of inflammatory cells (eg eosinophils, neutrophils, macrophages, monocytes, and platelets) which are associated with asthma. As mast cell stabilisation is not sufficient on its own to explain the anti-asthmatic activity of this chromone type drug, other as yet incompletely resolved mechanisms must be involved.
External links